{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:56:59Z","timestamp":1767992219937,"version":"3.49.0"},"reference-count":31,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2007,8,9]],"date-time":"2007-08-09T00:00:00Z","timestamp":1186617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Aims\u2003<\/jats:bold> Buprenorphine is marketed in a sublingual formulation for treatment of opioid dependence. A transdermal formulation has been developed that may provide extended relief from opioid withdrawal, reduce required clinic visits and improve adherence, while having less potential for diversion and abuse. This study evaluated the safety and biodelivery (blood levels) of this transdermal buprenorphine formulation (i.e. buprenorphine patch), and its apparent efficacy in suppressing the opioid withdrawal syndrome.<\/jats:p><jats:p><jats:bold>Design\u2003<\/jats:bold> Open\u2010label, first\u2010in\u2010humans trial.<\/jats:p><jats:p><jats:bold>Setting\u2003<\/jats:bold> A residential research facility.<\/jats:p><jats:p><jats:bold>Participants\u2003<\/jats:bold> Nine physically dependent opioid\u2010users completed the 10\u2010day opioid detoxification study.<\/jats:p><jats:p><jats:bold>Intervention\u2003<\/jats:bold> Each volunteer received a single patch application that remained in place for 3\u2003days. The formulation has shown an average delivery of 1.9\u2003mg\/day of buprenorphine over 3\u2003days in pre\u2010clinical evaluation.<\/jats:p><jats:p><jats:bold>Measures\u2003<\/jats:bold> Physiological, behavioral, subjective and observer ratings of opioid withdrawal and opioid agonist effects were collected.<\/jats:p><jats:p><jats:bold>Findings\u2003<\/jats:bold> Overall, the patch appeared safe and well tolerated. There were no serious adverse events, and no opioid intoxication following patch application. Oxygen saturation, heart rate, blood pressure, skin temperature and pupil diameter remained well within normal ranges. Buprenorphine blood levels peaked 48\u2003hours after patch application at a concentration of 0.60\u2003ng\/ml. Volunteers' self\u2010reports of the presence and severity of withdrawal symptoms were reduced by approximately 50% on the 3\u2003days of patch application. Withdrawal symptoms increased marginally upon patch removal. Administration of opioid rescue medication was eliminated within 6\u2003hours of patch application, and increased slightly upon patch removal.<\/jats:p><jats:p><jats:bold>Conclusions\u2003<\/jats:bold> The significant biodelivery of buprenorphine and the suppression of the opioid withdrawal syndrome during patch application and its reappearance after patch removal indicate clinically useful pharmacodynamic activity. Transdermal buprenorphine may be a useful opioid detoxification treatment that reduces compliance concerns, and delivers buprenorphine in a formulation less likely to be diverted to illicit use.<\/jats:p>","DOI":"10.1111\/j.1360-0443.2007.01944.x","type":"journal-article","created":{"date-parts":[[2007,8,9]],"date-time":"2007-08-09T15:49:44Z","timestamp":1186674584000},"page":"1648-1656","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of a transdermal buprenorphine formulation in opioid detoxification"],"prefix":"10.1111","volume":"102","author":[{"given":"Ryan K.","family":"Lanier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Umbricht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elie S.","family":"Nuwayser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George E.","family":"Bigelow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480200058024"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.7.1025"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1998.9344753.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(01)00202-2"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.13"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(88)90454-7"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2002.00215.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)92961-7"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1990.tb03088.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1992.tb03224.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(93)90036-P"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703100706"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00958.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.V35N7p492"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/22.6.430"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/65.1.107"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(02)00304-1"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2006.03.037"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922008236"},{"key":"e_1_2_6_21_2","volume-title":"An Open\u2010Label, Partially Blinded, Balanced 4\u2003\u00d7\u20034 Latin Square Crossover Study to Evaluate the Pharmacokinetic and Dose\u2010Proportionality of Buprenorphine When Administered in Sublingual Tablets Alone or in Combination with Naloxone in Nondependent Opiate Users.","author":"Jones R. T.","year":"1997"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2003.08.006"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-15-5-829"},{"key":"e_1_2_6_24_2","first-page":"449","article-title":"Buprenorphine's physical dependence potential: antagonist\u2010precipitated withdrawal in humans","volume":"276","author":"Eissenberg T.","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1006\/abio.2002.5673"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(99)00012-5"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(03)00058-9"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2003.11.008"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1998.93454910.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01348.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/20.6.369"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00192-6"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1360-0443.2007.01944.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1360-0443.2007.01944.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:10:23Z","timestamp":1697541023000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1360-0443.2007.01944.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,9]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1111\/j.1360-0443.2007.01944.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1360-0443.2007.01944.x","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,9]]},"assertion":[{"value":"2007-08-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}